Tag: Resistance to therapy
Search News
Scientists uncover a promising strategy to combat leukaemia resistance
18th May 2023
Research reveals a vulnerability in leukaemia cells that causes them to fill with toxic fatty acids
Read more
Ovarian cancer’s protective barrier: how the tumour matrix teaches cells to disarm immune attack
15th May 2023
The results suggest new strategies to overcome the cancer’s defences and treat patients more effectively
Read more
Understanding the role of cancer’s circular genome in tumour evolution
23rd September 2022
New research, co-led by Dr Benjamin Werner from Barts Cancer Institute at Queen Mary University of London, indicates that the circular DNA structures present in around a third of cancers lead to extensive genetic diversity within tumours, giving them the ability to adapt rapidly to environmental stress and resist targeted cancer treatment.
Read more
BCI researcher receives new Pancreatic Cancer UK Fellowship
20th July 2022
Congratulations to Dr Audrey Lumeau, Postdoctoral Researcher at Barts Cancer Institute, Queen Mary University of London, who has received a Career Foundation Fellowship from the charity Pancreatic Cancer UK to investigate chromosomal instability in pancreatic cancer and its role in therapy resistance.
Read more
In conversation with Professor Marco Gerlinger
20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more
Rewiring the biology of leukaemia cells to reverse drug resistance
20th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.
Read more